CMIC Co. Ltd.
Latest From CMIC Co. Ltd.
February brings new executives at Japan's Astellas, Kyowa Hakko Bio and CMIC. Meanwhile, China FDA deputy commissioner has departed to become the head of an influential academic organization.
As investment pours into Chinese biologic startups, a talent hunt is on, underscored by two announcements of new senior appointments at CANbridge and Zai Lab. Meanwhile, clinical research organization ICON has appointed new leadership for Asia and Meiji Seika is strengthening its CNS business.
Shanghai Pharma has a new CEO after a large shakeup, and GSK appoints an interim head of discovery in China after Nature Medicine fallout. Mindray returns to co-CEO model, and personnel changes occur at Astellas, Merck Serono, Daiichi Sankyo and RDPAC.
China’s National Health and Family Planning Commission appoints eight deputy commissioners. Astellas hires a global head of pharmacovigilance from rival Takeda, while Chinese domestic drug makers lure executives away from multinational firms.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- CMIC Co. Ltd.
- Senior Management
- Kazuo Nakarmura, CEO
- Contact Info
CMIC Co. Ltd.
Phone: (81) 35745 7070
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.